Do all patients with suspicious prostate cancer need Multiparametric Magnetic Resonance Imaging before prostate biopsy?
https://doi.org/10.4081/aiua.2022.1.32
Accepted: December 23, 2021
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Objectives: Multiparametric magnetic resonance imaging (mpMRI) is a useful tool to diagnose prostate cancer (PCa) but its cost is not negligible. In order to reduce costs and minimize time to diagnosis, it is necessary to establish which patients benefit the most from doing mpMRI prior to prostate biopsy (PB). Our aim was to test if mpMRI still predicts PCa and clinically significant PCa (csPCa) in patients with high clinical suspicion of cancer, defined as prostate specific antigen (PSA) > 10 ng/ml, PSA-Density (PSAD) > 0.15 ng/ml/cc or suspicious digital rectal examination (DRE).
Materials and methods: We retrospectively collected data on 206 patients who underwent mpMRI before PB at our Department from January 2017 to July 2018. mpMRI results were classified using Prostate Imaging Reporting and Data System (PI-RADS) version 2. In primary analysis, we evaluated the association of mpMRI with PCa and csPCa and stratified this model for low and high clinical suspicion of cancer. In secondary analysis, we determined the rate of negative PB results in patients with high suspicion of cancer and compared theses rates with those obtained if only those with PI-RADS 3-5 would be biopsied.
Results: In primary analysis and overall, mpMRI was predictive of PCa and csPCa. In stratified analysis, mpMRI was still significantly associated with csPCa in patients with PSA > 10 ng/ml and PSAD > 0.15 ng/ml/cc, but not in those with suspicious DRE. In secondary analysis, negative result rates were lower if only patients with PI-RADS 3-5 were biopsied, even in subgroups with high suspicion of cancer based on PSA and PSAD. In patients with suspicious DRE, however, the rate of negative results did not change significantly if only patients with PI-RADS 3-5 were biopsied.
Conclusions: mpMRI is still useful in predicting csPCa in patients with PSA > 10 ng/mL and PSAD > 0.15 ng/ml/cc. If DRE is suspicious, though, mpMRI might be no longer useful in the prediction of PCa.
Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61:1079-92. DOI: https://doi.org/10.1016/j.eururo.2012.02.054
Aminsharifi A, Howard L, Wu Y, et al. Prostate specific antigen density as a predictor of clinically significant prostate cancer when the prostate specific antigen is in the diagnostic gray zone: defining the optimum cutoff point stratified by race and body mass index. J Urol. 2018; 200:1-9. DOI: https://doi.org/10.1016/j.juro.2018.05.016
Galosi AB, Palagonia E, Scarcella S, et al. Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: up-date of the Italian Society of Integrated Diagnostic in Urology. Arch Ital Urol Androl. 2021; 93:92-100. DOI: https://doi.org/10.4081/aiua.2021.1.92
Rabbani F, Stroumbakis N, Kava BR, et al. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol. 1998;159:1247-50. DOI: https://doi.org/10.1016/S0022-5347(01)63574-2
Grenabo Bergdahl A, Wilderang U, Aus G, et al. Role of magnetic resonance imaging in prostate cancer screening: a pilot study within the Goteborg randomised screening trial. Eur Urol. 2016; 70:566-73. DOI: https://doi.org/10.1016/j.eururo.2015.12.006
Pokorny MR, de Rooij M, Duncan E, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol. 2014; 66:22-9. DOI: https://doi.org/10.1016/j.eururo.2014.03.002
Brizmohun Appayya M, Sidhu HS, Dikaios N, et al. Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI. Br J Radiol. 2018; 91:20170645. DOI: https://doi.org/10.1259/bjr.20170645
Barnett CL, Davenport MS, Montgomery JS, et al. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. BJU Int. 2018; 122:50-8. DOI: https://doi.org/10.1111/bju.14151
Radtke JP, Wiesenfarth M, Kesch C, et al. Combined clinical parameters and multiparametric magnetic resonance imaging for advanced risk modeling of prostate cancer-patient-tailored risk stratification can reduce unnecessary biopsies. Eur Urol. 2017; 72:888-96. DOI: https://doi.org/10.1016/j.eururo.2017.03.039
Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet (London, England). 2014; 384:2027-35. DOI: https://doi.org/10.1016/S0140-6736(14)60525-0
Meng X, Rosenkrantz AB, Mendhiratta N, et al. Relationship between prebiopsy multiparametric magnetic resonance imaging (MRI), biopsy indication, and MRI-ultrasound fusion-targeted prostate biopsy outcomes. Eur Urol. 2016; 69:512-7. DOI: https://doi.org/10.1016/j.eururo.2015.06.005
Stanzione A, Creta M, Imbriaco M, et al. Attitudes and perceptions towards multiparametric magnetic resonance imaging of the prostate: A national survey among Italian urologists. Arch Ital Urol Androl. 2020; 92:291-296. DOI: https://doi.org/10.4081/aiua.2020.4.291
Panebianco V, Barchetti G, Simone G,, et al. Negative multiparametric magnetic resonance imaging for prostate cancer: what’s next? Eur Urol. 2018; 74:48-54. DOI: https://doi.org/10.1016/j.eururo.2018.03.007
Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANMESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. https://uroweb.org/wp-content/uploads/EAU-EANM-ESTRO_ESUR_ISUP_SIOG-Guidelines-on-Prostate-Cancer-2021.pdf
Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol.2016; 69:16-40. DOI: https://doi.org/10.1016/j.eururo.2015.08.052
Washino S, Okochi T, Saito K, et al. Combination of prostate imaging reporting and data system (PI-RADS) score and prostatespecific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients. BJU Int. 2017;119:225-33. DOI: https://doi.org/10.1111/bju.13465
Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet (London, England). 2017; 389:815-22. DOI: https://doi.org/10.1016/S0140-6736(16)32401-1
Cormio L, Cindolo L, Troiano F, et al. Development and internal validation of novel nomograms based on benign prostatic obstructionrelated parameters to predict the risk of prostate cancer at first prostate biopsy. Front Oncol. 2018; 8:438. DOI: https://doi.org/10.3389/fonc.2018.00438
Komai Y, Numao N, Yoshida S, et al. High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy. J Urol. 2013;190:867-73. DOI: https://doi.org/10.1016/j.juro.2013.03.078
Ekin RG, Zorlu F, Akarken I, et al. Anterior apical cores in the initial prostate biopsy does not increase detection of significant prostate cancer. Urol J. 2015; 12:2084-9.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
